The long awaited global review on antimicrobial resistance by economist Lord Jim ONeill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-05-20 18:59:002016-05-20 18:59:00AMR Report: Test before you treat
Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.
https://european-biotechnology.com/wp-content/uploads/2024/04/doude-van-troostwijk.jpg236210h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-05-17 22:18:002016-05-17 22:18:00Marketing man
Molecular Devices®, market leader in microplate reader technology for over 25 years, has announced the launch of its SpectraMax® i3 Multi-Mode Detection Platform with SpectraMax® MiniMax® Imaging Cytometer.
Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimers disease. The news follows a recently announced R&D collaboration with Biogen.
The Oligo PRO 96XT system provides fast, automated and economical size-based purity analysis of single stranded DNA and RNA oligonucleotides, and double stranded RNA interference (RNAi) products.
Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genaes research services.
https://european-biotechnology.com/wp-content/uploads/2024/04/epx_placeholder_610.png200610h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-05-06 10:33:002016-05-06 10:33:00The doctor is in
https://european-biotechnology.com/wp-content/uploads/2024/04/ulf-hannelius.jpg237210h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-05-03 22:19:002016-05-03 22:19:00Building a diabetes major
Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-05-03 19:20:002016-05-03 19:20:00Ipsen and Oncodesign partner in R&D
AMR Report: Test before you treat
Latest NewsThe long awaited global review on antimicrobial resistance by economist Lord Jim ONeill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
CRISPR patent deal for Bayer
Latest NewsBayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
Marketing man
AppointmentsHansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.
SpectraMax® i3 Multi-Mode Microplate Detection Platform
ProductsMolecular Devices®, market leader in microplate reader technology for over 25 years, has announced the launch of its SpectraMax® i3 Multi-Mode Detection Platform with SpectraMax® MiniMax® Imaging Cytometer.
€21.5m for Oxford stem cell spinout
Latest NewsNewly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
€39m for neurodegeneration therapies
Latest NewsSwiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimers disease. The news follows a recently announced R&D collaboration with Biogen.
The Oligo PRO 96XT System
ProductsThe Oligo PRO 96XT system provides fast, automated and economical size-based purity analysis of single stranded DNA and RNA oligonucleotides, and double stranded RNA interference (RNAi) products.
The doctor is in
AppointmentsBelgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genaes research services.
Building a diabetes major
AppointmentsDiabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.
Ipsen and Oncodesign partner in R&D
Latest NewsIpsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.